Clinical Trial Update: JAM3 as a Prognostic Biomarker in Muscle-Invasive Urothelial Carcinoma: Correlation With Therapeutic Response, and Survival Outcomes

View source ↗

Summary

This clinical trial update reports on investigating JAM3 as a prognostic biomarker in muscle-invasive urothelial carcinoma (bladder cancer) and its correlation …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma of the Bladder

Snippet

Sponsor: Zeinab Yahia Zaki | Conditions: Urothelial Carcinoma Bladder | Status: NOT_YET_RECRUITING